CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy

Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer

(2017) Emi Tokuda et al.   HUMAN PATHOLOGY

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

(2017) W. Fraser Symmans et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

(2017) Carsten Denkert et al.   LANCET

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

(2017) Norikazu Masuda et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer

(2016) Min Chong Kim et al.   ANNALS OF SURGICAL ONCOLOGY

Impact of Expression of Vimentin and Axl in Breast Cancer

(2016) Kimihiro Tanaka et al.   Clinical Breast Cancer

BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane

(2016) T. Ishikawa et al.   EJSO

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

(2016) Kohei Shitara et al.   Gastric Cancer

Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer

(2016) Tatsuya Takayama et al.   MEDICAL ONCOLOGY

Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality

(2016) Masayuki Hagiwara et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

BRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy

(2015) Sadako Akashi-Tanaka et al.   Clinical Breast Cancer

Induction of CD44 Variant 9-Expressing Cancer Stem Cells Might Attenuate the Efficacy of Chemoradioselection and Worsens the Prognosis of Patients with Advanced Head and Neck Cancer

(2015) Takeichiro Aso et al.   PLoS One

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

New Strategies for Triple-Negative Breast Cancer--Deciphering the Heterogeneity

(2014) I. A. Mayer et al.   CLINICAL CANCER RESEARCH

Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease

(2013) Janice Diaz et al.   BREAST CANCER RESEARCH AND TREATMENT

CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence

(2013) K Hirata et al.   BRITISH JOURNAL OF CANCER

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Vimentin as a poor prognostic factor for triple-negative breast cancer

(2013) Nami Yamashita et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cancer Stem Cells: Current Status and Evolving Complexities

(2012) Jane E. Visvader et al.   Cell Stem Cell

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

(2011) Makiko Ono et al.   BREAST CANCER RESEARCH AND TREATMENT

CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth

(2011) Takatsugu Ishimoto et al.   CANCER CELL

Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients

(2011) Katsuya Nakai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY